A Phase II Study of UCN-01 in Combination With Topotecan in Patients With SCLC Who Relapsed or Progressed greater than or equal to 3 Months After Completing First-Line Platinum-Based Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2018
At a glance
- Drugs Topotecan (Primary) ; UCN 01 (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 11 Jul 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 22 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 22 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.